Biomarin Pharmaceutical Stock Forecast - 8 Period Moving Average

BMRN Stock  USD 64.34  0.15  0.23%   
The 8 Period Moving Average forecasted value of Biomarin Pharmaceutical on the next trading day is expected to be 63.61 with a mean absolute deviation of 1.27 and the sum of the absolute errors of 67.53. Biomarin Stock Forecast is based on your current time horizon. Although Biomarin Pharmaceutical's naive historical forecasting may sometimes provide an important future outlook for the firm, we recommend always cross-verifying it against solid analysis of Biomarin Pharmaceutical's systematic risk associated with finding meaningful patterns of Biomarin Pharmaceutical fundamentals over time.
  
At this time, Biomarin Pharmaceutical's Inventory Turnover is very stable compared to the past year. As of the 7th of February 2025, Receivables Turnover is likely to grow to 3.58, while Payables Turnover is likely to drop 1.56. . As of the 7th of February 2025, Net Income Applicable To Common Shares is likely to grow to about 170.9 M, while Common Stock Shares Outstanding is likely to drop about 127.6 M.

Open Interest Against 2025-04-17 Biomarin Option Contracts

Although open interest is a measure utilized in the options markets, it could be used to forecast Biomarin Pharmaceutical's spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Biomarin Pharmaceutical's options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Biomarin Pharmaceutical stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Biomarin Pharmaceutical's open interest, investors have to compare it to Biomarin Pharmaceutical's spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Biomarin Pharmaceutical is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Biomarin. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
An 8-period moving average forecast model for Biomarin Pharmaceutical is based on an artificially constructed time series of Biomarin Pharmaceutical daily prices in which the value for a trading day is replaced by the mean of that value and the values for 8 of preceding and succeeding time periods. This model is best suited for price series data that changes over time.

Biomarin Pharmaceutical 8 Period Moving Average Price Forecast For the 8th of February

Given 90 days horizon, the 8 Period Moving Average forecasted value of Biomarin Pharmaceutical on the next trading day is expected to be 63.61 with a mean absolute deviation of 1.27, mean absolute percentage error of 2.82, and the sum of the absolute errors of 67.53.
Please note that although there have been many attempts to predict Biomarin Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Biomarin Pharmaceutical's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).

Biomarin Pharmaceutical Stock Forecast Pattern

Backtest Biomarin PharmaceuticalBiomarin Pharmaceutical Price PredictionBuy or Sell Advice 

Biomarin Pharmaceutical Forecasted Value

In the context of forecasting Biomarin Pharmaceutical's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Biomarin Pharmaceutical's downside and upside margins for the forecasting period are 61.97 and 65.25, respectively. We have considered Biomarin Pharmaceutical's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Market Value
64.34
63.61
Expected Value
65.25
Upside

Model Predictive Factors

The below table displays some essential indicators generated by the model showing the 8 Period Moving Average forecasting method's relative quality and the estimations of the prediction error of Biomarin Pharmaceutical stock data series using in forecasting. Note that when a statistical model is used to represent Biomarin Pharmaceutical stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.
AICAkaike Information Criteria104.4459
BiasArithmetic mean of the errors 0.0165
MADMean absolute deviation1.2742
MAPEMean absolute percentage error0.0199
SAESum of the absolute errors67.5325
The eieght-period moving average method has an advantage over other forecasting models in that it does smooth out peaks and valleys in a set of daily observations. Biomarin Pharmaceutical 8-period moving average forecast can only be used reliably to predict one or two periods into the future.

Predictive Modules for Biomarin Pharmaceutical

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Biomarin Pharmaceutical. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
62.7164.3465.97
Details
Intrinsic
Valuation
LowRealHigh
51.9753.6070.77
Details
Bollinger
Band Projection (param)
LowMiddleHigh
59.5464.0568.57
Details
26 Analysts
Consensus
LowTargetHigh
88.8797.66108.41
Details

Other Forecasting Options for Biomarin Pharmaceutical

For every potential investor in Biomarin, whether a beginner or expert, Biomarin Pharmaceutical's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Biomarin Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Biomarin. Basic forecasting techniques help filter out the noise by identifying Biomarin Pharmaceutical's price trends.

View Biomarin Pharmaceutical Related Equities

 Risk & Return  Correlation

Biomarin Pharmaceutical Technical and Predictive Analytics

The stock market is financially volatile. Despite the volatility, there exist limitless possibilities of gaining profits and building passive income portfolios. With the complexity of Biomarin Pharmaceutical's price movements, a comprehensive understanding of forecasting methods that an investor can rely on to make the right move is invaluable. These methods predict trends that assist an investor in predicting the movement of Biomarin Pharmaceutical's current price.

Biomarin Pharmaceutical Market Strength Events

Market strength indicators help investors to evaluate how Biomarin Pharmaceutical stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Biomarin Pharmaceutical shares will generate the highest return on investment. By undertsting and applying Biomarin Pharmaceutical stock market strength indicators, traders can identify Biomarin Pharmaceutical entry and exit signals to maximize returns.

Biomarin Pharmaceutical Risk Indicators

The analysis of Biomarin Pharmaceutical's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Biomarin Pharmaceutical's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting biomarin stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:
Check out Historical Fundamental Analysis of Biomarin Pharmaceutical to cross-verify your projections.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.607
Earnings Share
1.66
Revenue Per Share
14.529
Quarterly Revenue Growth
0.283
Return On Assets
0.03
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.